Colby Pharmaceuticals
HCID Member | Biotech Specialty Pharma
1095 Colby Avenue, Suite C
Menlo Park, CA 94025 USA
phone: 650-333-3150
fax: 650-323-6215
Symbol Private
Founded 0
Employees 3
www.colbypharmaceuticals.com
Research Sector Biotech Specialty Pharma
Summary Description
Small molecule therapeutics for the treatment of prostate cancer
Management
David Zarling PhD MBA, Chief Executive Officer; K Narducy PhD MBA, President, Drug Development; Hirak Basu PhD, Chief Scientific Officer; M Mehta MD, Chief Medical Officer
Keywords
small molecule therapeutics, oxidative stress, cancer, prostate, oncology, urology

Comment | Printable Version | Aug. 29, 2008
If you work for Colby Pharmaceuticals and want to update this profile, click here

Description
Colby Pharmaceuticals develops small molecule therapeutics for the treatment of oxidative stress-induced major human diseases. The company has three in-licensed oncology drug candidates and has two internally generated New Chemical entity drugs in pre-clinical development.
Products / Services
CPC-100 is an antioxidant, anti-inflammatory and anti-androgenic oxidative stress inhibitor drug. It is used to treat patients receiving follow-up treatment for primary prostate cancer that are returning to the clinic with rising Prostate Specific Antigen (PSA) levels without evidence of tumor metastasis in bone or soft tissue.
Technology / Differentiation
There is an existing billion-dollar-plus market in drugs for prostate cancer patient populations with mid-stage prostate tumors. If clinical trials are successful, CPC-100 drug sales would strongly compete in this market. CPC-100 acts on multiple targets and benefits both androgen-dependent and androgen-independent prostate cancer. Competitive drugs lack therapeutic effect in androgen-independent prostate cancer.
Market / Customers
Prostate cancer is the most commonly diagnosed cancer in men; in the U.S., over 234,000 cases were diagnosed in 2006. It is also the leading cause of cancer fatality among U.S. men, directly causing over 27,000 deaths each year. Currently, there is no effective therapy for advanced prostate cancer.
Status
Colby plans to file its first investigational New Drug application to FDA and will sponsor a Phase I/IIa clinical trial for its lead drug, CPC-100, for the treatment of men with progressive prostate cancer.


2008-10-11-1393